For immediate release |
13 May 2011 |
Alliance Pharma plc
TR-1: Notification of major interest in shares
1. Identity of the issuer or the underlying issuer |
Alliance Pharma plc |
|||
2 Reason for the notification (please tick the appropriate box or boxes): |
||||
An acquisition or disposal of voting rights |
|
|||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
|||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|||
An event changing the breakdown of voting rights |
|
|||
Other (please specify): |
On market transfer between direct and indirect funds |
√ |
||
3. Full name of person(s) subject to the |
Aviva plc & its subsidiaries |
|||
4. Full name of shareholder(s) |
Registered Holder:
BNY Norwich Union Nominees Limited 3,404,351* Chase (GA Group) Nominees Limited 20,409,918*
*denotes direct interest
Chase Nominees Limited 502,486
|
|||
5. Date of the transaction and date on |
12 May 2011 |
|||
6. Date on which issuer notified: |
13 May 2011 |
|||
7. Threshold(s) that is/are crossed or |
10% to 9% Change at Direct Interest Level |
|||
8. Notified details: |
||||||||||||||||
A: Voting rights attached to shares |
||||||||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
||||||||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights |
||||||||||||
Direct |
Direct |
Indirect |
Direct |
Indirect |
||||||||||||
GB0031030819 |
24,316,755
|
24,316,755
|
24,316,755 |
23,814,269 |
502,486 |
9.96% |
0.21% |
|||||||||
|
||||||||||||||||
|
||||||||||||||||
B: Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
||||||||||||
|
|
|
|
|
||||||||||||
|
||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Exercise price |
Expiration date |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights
|
|||||||||||
|
|
|
|
|
Nominal |
Delta |
||||||||||
|
|
|||||||||||||||
|
||||||||||||||||
Total (A+B+C) |
||||||||||||||||
Number of voting rights |
Percentage of voting rights |
|||||||||||||||
24,316,755 |
10.17% |
|||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the |
||
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited: · Aviva plc (Parent Company) · Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) · Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) · Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
|
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
See Section 4 |
|
11. Number of voting rights proxy holder will cease |
|
|
12. Date on which proxy holder will cease to hold |
|
|
|
||
|
Figures are based on a revised total number of voting rights of 239,135,915, as per the company's Exercise of Share Options Announcement of 6 May 2011. |
|
14. Contact name: |
Michael Dunhill, Aviva plc |
|
15. Contact telephone number: |
01603 685988 |
|